Evidence map›Paper›PMID 35190953›Full record

ArticleMolecular neurobiology2022

Macamide B Pretreatment Attenuates Neonatal Hypoxic-Ischemic Brain Damage of Mice Induced Apoptosis and Regulates Autophagy via the PI3K/AKT Signaling Pathway.

Xiaoxia Yang, Mengxia Wang, Qian Zhou, Yanxian Bai, Jing Liu, Junhua Yang, Lixia Li, Guoying Li, Li Luo

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xiaoxia Yang *School of Biosciences & Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, People's Republic of China.
Mengxia Wang *Intensive Care Unit, Guangdong Second Provincial General Hospital, Guangzhou, 510317, Guangdong, People's Republic of China.
Qian ZhouSchool of Biosciences & Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, People's Republic of China.
Yanxian BaiSchool of Biosciences & Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, People's Republic of China.
Jing LiuSchool of Biosciences & Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, People's Republic of China.
Junhua YangSchool of Biosciences & Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, People's Republic of China.
Lixia LiSchool of Biosciences & Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, People's Republic of China.
Guoying LiSchool of Biosciences & Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, People's Republic of China. gzlgying820@163.com.
Li LuoSchool of Biosciences & Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, People's Republic of China. josephluoli@hotmail.com.ORCID http://orcid.org/0000-0002-3883-003X
Guangdong Pharmaceutical University · CNGuangdong Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lepidium meyenii (maca) is an annual or biennial herb from South America that is a member of the genus Lepidium L. in the family Cruciferae. This herb possesses antioxidant and antiapoptotic activities, enhances autophagy functions, prevents cell death, and protects neurons from ischemic damage. Macamide B, an effective active ingredient of maca, exerts a neuroprotective effect on neonatal hypoxic-ischemic brain damage (HIBD), but the mechanism underlying its neuroprotective effect is not yet known. The purpose of this study was to explore the effect of macamide B on HIBD-induced autophagy and apoptosis and its potential neuroprotective mechanism. The modified Rice-Vannucci method was used to induce HIBD in 7-day-old (P7) macamide B- and vehicle-pretreated pups. TTC staining was performed to evaluate the cerebral infarct volume in pups, the brain water content was measured to evaluate the neurological function of pups, neurobehavioural testing was conducted to assess functional recovery after HIBD, TUNEL and FJC staining was performed to detect cellular autophagy and apoptosis, and Western blot analysis was used to detect the levels of proteins in the pro-survival phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) signaling pathway and autophagy and apoptosis-related proteins. Macamide B pretreatment significantly decreases brain damage and improves the recovery of neural function after HIBD. At the same time, macamide B pretreatment activates the PI3K/AKT signaling pathway after HIBD, enhances autophagy, and reduces hypoxic-ischemic (HI)-induced apoptosis. In addition, 3-methyladenine (3-MA), an inhibitor of the PI3K/AKT signaling pathway, significantly inhibits the increase in autophagy levels, aggravates HI-induced apoptosis, and reverses the neuroprotective effect of macamide B on HIBD. Our data indicate that a macamide B pretreatment might regulate autophagy through the PI3K/AKT signaling pathway, thereby reducing HIBD-induced apoptosis and exerting neuroprotective effects on neonatal HIBD. Macamide B may become a new drug for the prevention and treatment of HIBD.

Indexed as

Hypoxia-Ischemia, BrainNeuroprotective AgentsAnimalsAnimals, NewbornApoptosisApoptosis Regulatory ProteinsAutophagyBrainMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionApoptosis Regulatory ProteinsNeuroprotective AgentsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktApoptosisAutophagyMacamide BNeonatal Hypoxic-ischemic Brain DamageNeuroprotectionPI3K/AKT

Identifiers

PMID35190953
OpenAlexW4212864541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.